My Review
By C.A.T
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by C.A.T
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 2
Reviews: 0
Episodes: 389
Description
Review
| Episode | Date |
|---|---|
|
11.OB:sec.1-18of18-APGAR & neonatal resuscitation
|
May 25, 2020 |
|
11.sec.1-17of18-Obstetric Bleeding
|
May 25, 2020 |
|
11.OB:sec.1-16of18-Disorders of the Placenta
|
May 25, 2020 |
|
11.OB:sec.1-15of18-OB hypertensive d/o:pathophysiology
|
May 25, 2020 |
|
11.OB:sec.1-14-18-Nonobstetrics Surgery during pregnancy
|
May 24, 2020 |
|
11.OB:sec.1-13of18-c/s: General Anesthesia
|
May 24, 2020 |
|
11.OB:sec.1-12of18-Uterotonic Drugs
|
May 24, 2020 |
|
11.OB:sec.1-11of18-Prematurity & tocolysis
|
May 24, 2020 |
|
11.OB:sec.1-10of18-Three Tier system for eval of FHR
|
May 22, 2020 |
|
11.OB:sec.1-9of18-Fetal Heart Rate
|
May 22, 2020 |
|
11.OB:sec.1-8of18-Total Spinal
|
May 22, 2020 |
|
11.OB-sec.1-7of18-Local Anesthetics
|
May 22, 2020 |
|
11.OB:sec.1-6of18-Labor Pain
|
May 22, 2020 |
|
11OB:sec.1-5of-18-Stages of Labor
|
May 22, 2020 |
|
11.OBstetrics:sec.4of18-The Uterus
|
May 22, 2020 |
|
11.Obstetrics:sec.1-3of18-Physiologic Changes during pregnan
|
May 21, 2020 |
|
11.Obstetrics:sec.1-2of18-Physiologic Changes during pregnan
|
May 21, 2020 |
|
11.Obstetrics:sec.1-of18-Physiologic changes during pregnanc
|
May 20, 2020 |
|
8.Neuraxial:sec.1-16of16-Cauda Equina & TNS
|
May 19, 2020 |
|
8.Neuraxial:sec.1-15of16-Antiplatelet & anticoagulants
|
May 19, 2020 |
|
8.Neuraxial:sec.1-14of16-Postdural puncture headache & menin
|
May 19, 2020 |
|
8.Neuraxial:sec.1-13of16-Neuraxial opioid side effects
|
May 19, 2020 |
|
8.Neuraxial:sec.1-12of16-Neuraxial Opioids
|
May 19, 2020 |
|
8.Neuraxial:11of16-Caudal Anesthesia
|
May 19, 2020 |
|
8.Neuraxial:sec.1-10of16-spinal & epidural needles
|
May 18, 2020 |
|
8.Neuraxial:sec.1-9of10-Baricity
|
May 18, 2020 |
|
8.Neuraxial:sec.1-8of16-Contraindications to Neuraxial Anest
|
May 18, 2020 |
|
8.Neuraxial:sec.1-7of16-systemic effects of Neuraxial Anesth
|
May 18, 2020 |
|
8.Neuraxial:sec.1-6of16-site of action, spread, differentia
|
May 18, 2020 |
|
8.Neuraxial:sec.1-5of16-Dermatomes
|
May 18, 2020 |
|
8.Neuraxial:sec.1-4of16-Sacral Anatomy
|
May 18, 2020 |
|
8.Neuraxial:sec.1-3of15-The epidural & SAB spaces
|
May 18, 2020 |
|
8.Neuraxial:sec1-2of16-Ligaments of the spinal column
|
May 18, 2020 |
|
8.Neuraxial:sec.1-1of16-Anatomy of the Back Bone
|
May 18, 2020 |
|
7.Neuro:sec3-15of15-Musculoskeletal dse part 2
|
May 16, 2020 |
|
7.Neuro:sec.3-14of15-selected Musculoskeletal dse
|
May 16, 2020 |
|
7.Neuro:sec.3-13of15-SLE
|
May 16, 2020 |
|
7.Neuro:sec.3-12of15-RA:Pathophys
|
May 16, 2020 |
|
7.Neuro:sec.3-11of15-Rheumatoid Arthritis
|
May 16, 2020 |
|
7.Neuro:sec.3-10of15-Scoliosis
|
May 15, 2020 |
|
7.Neuro:sec.3-9of15-Muscular Dystrophy
|
May 15, 2020 |
|
7.Neuro:sec.1-8of15-MH:treatment
|
May 15, 2020 |
|
7.Neuro:MH: Clinical Presentation
|
May 15, 2020 |
|
7.Neuro:sec.3-6of15-Malignant Hyperthermia
|
May 15, 2020 |
|
7.Neuro:sec.3-5of15-Familial Periodic Paralysis
|
May 15, 2020 |
|
7.Neuro:sec.3-4of15-Guillain-Barre Syndrome
|
May 15, 2020 |
|
7.Neuro:sec.3-3of15-Eaton-Lambert Syndrome (Myasthenic Syndr
|
May 15, 2020 |
|
7.Neuro:sec.3-2of15-MG:NMB & postop concerns
|
May 15, 2020 |
|
7.Neuro:sec.3-1of15-Myasthenia Gravis
|
May 15, 2020 |
|
7.Neuro:Sec.2-8of8-Amyotrophic Lateral Sclerosis
|
May 15, 2020 |
|
7.Neuro:sec.2-7of8-Autonomic Hyperreflexia
|
May 14, 2020 |
|
7.Neuro:sec.2-6of8-Acute Spinal cord injury: Neurogenic Shoc
|
May 14, 2020 |
|
7.Neuro:sec.2-5of8-Motor pathways: Corticospinal Tract
|
May 14, 2020 |
|
7.Neuro:sec.2-4of8-Sensory Pathways:Anyerolateral system-spi
|
May 14, 2020 |
|
7.Neuro:sec.2-3of8-Sensory pathway: Dorsal Column- Medial Le
|
May 14, 2020 |
|
7.Neuro:Sec.2-2of8-Anatomy Overview
|
May 14, 2020 |
|
7.Neuro:sec.2-1of8-Spinal Cord blood flow
|
May 14, 2020 |
|
7.Neuro:sec.1-16of16-Ischemic optic neuropathy & CRAO
|
May 14, 2020 |
|
7.Neuro:sec.1-15of16-Parkinson’s Disease
|
May 14, 2020 |
|
7.Neuro:sec.1-14of16-Alzheimer’s Disease
|
May 14, 2020 |
|
Neuro:sec.1-13of16-Anticonvulsant
|
May 14, 2020 |
|
7.Neuro:sec.1-12of16-seizure disorder
|
May 14, 2020 |
|
7.Neuro:sec.1-11of16-Traumatic Brain Injury
|
May 14, 2020 |
|
7.Neuro:Sec.1-10of16-Cerebral Aneurysm
|
May 13, 2020 |
|
7.Neuro:sec.1-9of16-ischemic Stroke
|
May 13, 2020 |
|
7.Neuro:sec.1-8of16-Cerebrovascular Anatomy
|
May 13, 2020 |
|
7.Neuro:sec.1-7of16-Intracranial HTN:treatment
|
May 13, 2020 |
|
7.Neuro:sec.1-6of16-ICP
|
May 13, 2020 |
|
7.Neuro:sec.1-5of16-CBF
|
May 13, 2020 |
|
7.Neuro:sec.1-4of16-CSF Dynamics and the BBB
|
May 13, 2020 |
|
7.Neuro:sec.1-3of16-Cranial Nerves
|
May 13, 2020 |
|
7.Neuro:sec.1-2of16-Gross structures of the Brain
|
May 13, 2020 |
|
7.Neuro-sec.1-1of16-CNS
|
May 13, 2020 |
|
6.Equipments:Sec.6:5of5-Electrocautery
|
Apr 11, 2020 |
|
6.Equipments:sec.6-4of5-Electricity in the O.R
|
Apr 11, 2020 |
|
6.Equipments:sec.6-3of5-BIS & PSI
|
Apr 11, 2020 |
|
6.Equipments:sec.6-2of5-EEG
|
Apr 11, 2020 |
|
6.Equipments:sec.6-1of5-Cerebral Oximetry
|
Apr 11, 2020 |
|
7.Equipments:sec.5-13of13-Pacemaker part 2
|
Apr 11, 2020 |
|
6.Equipments:sec.5-12of13-Pacemakers:Part1
|
Apr 11, 2020 |
|
6.Equipments:sec.5-11of13-Torsades de pointes
|
Apr 11, 2020 |
|
6.Equipments:sec.5-10of13-Wolff-Parkinson-White syndrome
|
Apr 11, 2020 |
|
6.Equipments:sec.5-9of13-Reentry pathways
|
Apr 10, 2020 |
|
6.Equipments:sec.5-8of13-Antidysrhythmic Medications
|
Apr 10, 2020 |
|
6.Equipments:sec.5-7of13-Heart Block
|
Apr 10, 2020 |
|
6.Equipmemts:sec.5-6of13-Selected rhythm disturbances
|
Apr 10, 2020 |
|
6.Equipments:sec.5-5of13-Axis Deviation
|
Apr 10, 2020 |
|
6.Equipments:sec.5-4of13-Vectors
|
Apr 10, 2020 |
|
6.Equipments:sec.5-3of13-EKG:Normal Values and Abnormalities
|
Apr 10, 2020 |
|
6.Equipments:sec.5-2of13-EKG and cardiac action potential
|
Apr 10, 2020 |
|
6.Equipments:sec.5-1of13-Cardiac Conduction system
|
Apr 10, 2020 |
|
6.Equipments:sec.4-12of12-Esophageal Doppler
|
Apr 10, 2020 |
|
6.Equipments:sec.4-11of12-Pulse Contour Analysis
|
Apr 10, 2020 |
|
6.Equipments:sec.4-10of12-Mixed venous oxygen saturation
|
Apr 10, 2020 |
|
6.Equipments:sec.4-9of12-Cardiac Output
|
Apr 10, 2020 |
|
6.Equipments:sec.4-8of12-PA catheter:Abnormal
|
Apr 10, 2020 |
|
6.Equipments:sec.4-7of12-PA cath tip placement
|
Apr 10, 2020 |
|
6.Equipments:sec.4-6of12-PA waveform
|
Apr 10, 2020 |
|
6.Equipments:sec.4-5of12-CVP:Abnormal waveform
|
Apr 09, 2020 |
|
6.Equipments:sec.4:4of12-CVP interpretation
|
Apr 09, 2020 |
|
6.Equipments:sec.4-3of12-CVP-normal waveform
|
Apr 09, 2020 |
|
6.Equipments:sec.4-2of12-CVP:placement
|
Apr 09, 2020 |
|
6.Equipments:sec.4-1of12-BP measurement
|
Apr 09, 2020 |
|
6.Equipments:sec.3-9of9-Measurement of Exhaled Gases
|
Apr 09, 2020 |
|
6.Equipments:sec.3-8of9-pulse ox limitation
|
Apr 09, 2020 |
|
6.Equipments:sec.3-7of9-Pulse oximetry
|
Apr 09, 2020 |
|
6.Equipments:sec.3-6of9-Pulse ox relation to oxyhgb curve
|
Apr 09, 2020 |
|
6.Equipments:sec.3-5of9-Pulse Oximeter
|
Apr 09, 2020 |
|
6.Equipments:sec.3-4of9-Causes of high & low ETCO2
|
Apr 09, 2020 |
|
6.Equipments:sec.3-3of9-Capnograph abnormal waveform
|
Apr 09, 2020 |
|
6.Equipments:sec.3-2of9-Capnography Waveform
|
Apr 09, 2020 |
|
6.Equipments:sec.3-1of9-Assessment of pulmonary resistance a
|
Apr 09, 2020 |
|
6.Equipmemts:sec.2-4of4-Bain system
|
Apr 09, 2020 |
|
6.Equipments:sec2-3of4-Mapleson Circuit
|
Apr 09, 2020 |
|
6.Equipments:sec2:2of4-Circle System
|
Apr 09, 2020 |
|
6.Equipments:sec.2-1of4-Classification of breathing circuits
|
Apr 09, 2020 |
|
6.Equipments:sec.1-26of26-OSHA RECOMMENDATION regarding inha
|
Apr 08, 2020 |
|
6.Equipments:sec.1-25of26-Scavenger system
|
Apr 08, 2020 |
|
6.Equipments:sec.1-24of26-High pressure alarm
|
Apr 08, 2020 |
|
6.Equipments:sec.1-23of26-Low pressure alarm
|
Apr 08, 2020 |
|
6.Equipments:sec.1-22of26-Amsorb plus
|
Apr 08, 2020 |
|
6.Equipments:sec.1-21of26-Soda Lime
|
Apr 08, 2020 |
|
6.Equipments:sec.1-20of26-Mechanical Ventilation
|
Apr 08, 2020 |
|
6.Equipments:sec.1-19of26-VCV vs PCV
|
Apr 08, 2020 |
|
6.Equipments:sec.1-18of26-Piston Ventilator
|
Apr 08, 2020 |
|
6.Equipments:sec.1-17of26-Pneumatic Bellows
|
Apr 08, 2020 |
|
6.Equipments:sec.1-16of26-Oxygen flush valve & ventilatory s
|
Apr 08, 2020 |
|
6.Equipmets:sec.1-15of27-Oxygen pipeline supply failure
|
Apr 08, 2020 |
|
6.Equipments:sec.1-14of26-Oxygen analyzer
|
Apr 08, 2020 |
|
6.Equipments:sec.1-13of26-Tec 6 Desflurane Vaporizer
|
Apr 08, 2020 |
|
6.Equipments:sec.1-12of26-Variable Bypass Vaporizer:Overview
|
Apr 08, 2020 |
|
6.Equipments:sec.1-11of26-Circuit Compliance
|
Apr 08, 2020 |
|
6.Equipments:sec.1-10of26-Fresh Gas Coupling
|
Apr 07, 2020 |
|
9.Equipments:sec.1-9of26-Flowmeter FiO2 calculation
|
Apr 07, 2020 |
|
6.Equipments:sec.1-8of26-Flowmeters & Reynolds Number
|
Apr 07, 2020 |
|
6.Equipments:sec.1-7of26-Hypoxia prevention safety device
|
Apr 07, 2020 |
|
6.Equipments:sec.1-6of26-Failsafe device
|
Apr 07, 2020 |
|
6.Equipments:sec.1-5of26-Safe Handling of Gas Cylinders
|
Apr 07, 2020 |
|
6.Equipments:sec.1-4of26-Gas Cylinder
|
Apr 07, 2020 |
|
6.Equipments:sec.1-3of26-DISS & PISS
|
Apr 07, 2020 |
|
6.Equipments:sec.1-2of26-The SPDD Model
|
Apr 07, 2020 |
|
6.Equipment:sec.1-1of26-The anesthesia Machine
|
Apr 07, 2020 |
|
5.Pharmacology2:sec.4:11of11-Antagonist
|
Apr 07, 2020 |
|
5.Pharmacology2:sec.4-10of11-Partial agonist
|
Apr 07, 2020 |
|
5.Pharmacology2:sec.4-9of11-skeletal muscle rigidity
|
Apr 07, 2020 |
|
5.Pharmacology2:sec.4-8of11-Methadone
|
Apr 07, 2020 |
|
5.Pharmacology2:sec4-7of11-Remifentanil
|
Apr 07, 2020 |
|
5.Pharmacology2:sec.4-6of11-Alfentanil
|
Apr 07, 2020 |
|
5.Pharmacology2:sec.4-5of11-Meperidine
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.4-4of11-Metabolism
|
Apr 06, 2020 |
|
5.Pharmacologu2:sec.2-3of11-Relative potency and dependence
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.4-2of11-systemic effects
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.4-1of11-MOA pain
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2-5of5-Sugammadex
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2-4of5-Muscarinic Antagonists:side effec
|
Apr 06, 2020 |
|
5.Pharmacology2:sec3-3of5-Cholinergic side effects
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.3-2of5-Pharmacokinetic Neostigmine
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.3-1of5-AchE inhibitors:MOA
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2-17of17-Anaphylaxis & NMB
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2-16of17-CV effects of NMB
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2:15of17-Factors that potentiate NM bloc
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2-14of17-Metabolism of Nondepolarizers
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2-13of17-Potency
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2-12of17-Diseases with altered responses
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2-11of17-Post-op myalgia with sux
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2-10of17-Sux Black Box warning
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2-9of17-Dibucaine Test
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2-8of17-Factors that reduce pseudocholin
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2-7of17-Synonym for pseudocholinesterase
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2-6of17-Succinylcholine side effects
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.-5of17-Testing recovery from NM blockade
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2-4of17-Phase1 vs Phase 2 block
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2-3of17-Mechanism of fade
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2-2of17-Extrajunctional Receptors
|
Apr 06, 2020 |
|
5.Pharmacology2:sec.2-1of17-Neuromuscular Junction Physiolog
|
Apr 05, 2020 |
|
5.Pharmacology2:sec.1-15of15-Additives
|
Apr 05, 2020 |
|
5.Pharmacology2:sec.1-14of15-Emla Cream
|
Apr 05, 2020 |
|
5.Pharmacology2:sec.1-13of15-Methemoglobinemia
|
Apr 05, 2020 |
|
5.Pharmacology2:sec.1-12of15-Tumescent Anesthesia
|
Apr 05, 2020 |
|
5.Pharmacology2:sec.1-11of15- Treatment for LAST
|
Apr 05, 2020 |
|
5.Pharmacology2:sec.1-10-15-LAST
|
Apr 05, 2020 |
|
5.Pharmacology2:sec.1-9of10-Maximum allowable dose
|
Apr 05, 2020 |
|
5.Pharmacology2:sec.1-8of15-uptake & termination of action
|
Apr 05, 2020 |
|
5.Pharmacology2:sec.1-7of15-Acid base chemistry
|
Apr 05, 2020 |
|
5.Pharmacology2:sec.1-6of15-onset, potency, Duration of Acti
|
Apr 05, 2020 |
|
5.Pharmacology2:sec.1-5of15-Esters & Amides
|
Apr 05, 2020 |
|
5.Pharmacology2:sec1-4of15-MOA
|
Apr 05, 2020 |
|
5.Pharmacology2:sec.3of15-The action potential & effect ofLA
|
Apr 05, 2020 |
|
5.Pharmacology2:sec.1-2of15-voltage gated sodium channel
|
Apr 05, 2020 |
|
5.Pharmacology2.:sec.1-1of15-Peripheral Nerves
|
Apr 05, 2020 |
|
4.Pharmacology1:sec.5-11of11-Evoked Potential Monitoring
|
Apr 04, 2020 |
|
4.Pharmacology1:sec.5-10of11-Neurophysiologic effects
|
Apr 04, 2020 |
|
4.Pharmacology1:sec.4-9of11-Pulmonary effects:PaO2
|
Apr 04, 2020 |
|
4.Pharmacology1:sec.5-8of11-Pulmonary effects:PaCO2
|
Apr 04, 2020 |
|
4.Pharmacology1:sec.4-7of11-Cardiovascular effects
|
Apr 03, 2020 |
|
4.Pharmacology1:sec5:6of11-site of anesthetic action
|
Apr 02, 2020 |
|
4.Pharmacology1:sec.5-5of11-MOA:New way of Thinking
|
Apr 02, 2020 |
|
4.Pharmacology1:sec.5-4of11-MOA-old way of thinking
|
Apr 02, 2020 |
|
4.Pharmacology1:sec.5-3of11-MAc:Factors that affect Potency
|
Apr 02, 2020 |
|
4.Pharmacology1:sec.5-2of11-MAC
|
Apr 02, 2020 |
|
4.Pharmacology1:sec.5-1of11-Nitrous Oxide:Peculiarities
|
Apr 02, 2020 |
|
4.Pharmacology1:sec.4-10of10-Cardiac Shunti and FA/Fi
|
Apr 02, 2020 |
|
4.Pharmacology:sec.4-9of-10-second Gas effect
|
Apr 02, 2020 |
|
4.Pharmacology1:sec.4-8of10-Concentration Effect
|
Apr 02, 2020 |
|
4.Pharmacology1:sec.4-7of10-Hepatic Metabolism of Inhalation
|
Apr 02, 2020 |
|
4.Pharmacology1:sec.4-6of-10-Distribution
|
Apr 02, 2020 |
|
4.Pharmacology1:sec.4-5of10: factors affecting FA/FI
|
Apr 02, 2020 |
|
4.Pharmacology1:sec.4-4of10:FA/FI curves
|
Apr 02, 2020 |
|
4.Pharmacology1:sec.4-3of10-Solubility and the blood:Gas coe
|
Apr 02, 2020 |
|
4.Pharmacology1:sec.4-2of10-Physical properties
|
Apr 02, 2020 |
|
4.Pharmacology1:sec.4-1of10-Chemical Structures
|
Apr 02, 2020 |
|
4.Pharmacology:sec.3-10of10-Flumazenil
|
Apr 01, 2020 |
|
4.Pharmacology1-sec.3-9of10-Benzodiazepine
|
Apr 01, 2020 |
|
4.Pharmacology1:sec.3-8of10-Dexmedetomidine
|
Apr 01, 2020 |
|
4.Pharmacology1:sec.3-7of10-Barbiturates
|
Apr 01, 2020 |
|
4.Pharmacology1:sec.6-10-Etomidate Part2
|
Apr 01, 2020 |
|
4.Pharmacology1:sec.3-5of10-Etomidate
|
Apr 01, 2020 |
|
4.Pharmacology1:sec.3-4of10-Ketamine
|
Apr 01, 2020 |
|
4.Pharmacology1:sec.3-3of10-Fospropofol
|
Apr 01, 2020 |
|
4.Pharmacology1:sec.3-2of10-Propofol Part2
|
Apr 01, 2020 |
|
4.Pharmacology1:sec.3-1of10-Propofol
|
Apr 01, 2020 |
|
4.Pharmacology1:sec2-5of5-Stereochemistry,Enantiomers
|
Mar 31, 2020 |
|
4.Pharmacology1:sec.2-4of5-ED50,LD50,Therapeutic index
|
Mar 31, 2020 |
|
4.Pharmacology1:sec.2-3of5-Agonist, Antagonist
|
Mar 31, 2020 |
|
4.Pharmacology1:sec.2-2of5-Dose Response Curve
|
Mar 31, 2020 |
|
4.Pharmacology1:sec.2-1of5-Overview Pharmacodynamics
|
Mar 31, 2020 |
|
4.Pharmacology1-sec.1-13of13-Metabolism in the Plasma
|
Mar 31, 2020 |
|
4.Pharmacology1-sec.1-12of13-Renal Elimination
|
Mar 31, 2020 |
|
4.Pharmacology1-sec.1-11of13-P450 enzymes
|
Mar 31, 2020 |
|
4.Pharmacology1-sec.1-10of13-Hepatic Clearance
|
Mar 31, 2020 |
|
4.Pharmacology1:sec.1-9of13-phase 1,2,3 reactions
|
Mar 31, 2020 |
|
4.Pharmacology-sec.1-8of13-Zero vs. First Order Kinetics
|
Mar 31, 2020 |
|
4.Pharmacology:sec.1-7of13-Plasma Protein Binding
|
Mar 31, 2020 |
|
4.Pharmacology:sec.1-6of13-Ion Trapping
|
Mar 31, 2020 |
|
4.Pharcmacology-sec.1-5of13-pKa,pH and Ionization
|
Mar 31, 2020 |
|
4.Pharmacology:sec.1-4of13-Elimination Half-time and context
|
Mar 31, 2020 |
|
4. Pharmacology 1:sec1-3of13-Multi-compartment Models
|
Mar 31, 2020 |
|
4.Pharm1-sec.1-2of13-Clearance & Steady state
|
Mar 28, 2020 |
|
4.Pharm1-sec.1-1of13-Volume of Distribution
|
Mar 28, 2020 |
|
3.Cardiac:sec.3-23of23-Subclavian Steal Syndrome
|
Mar 26, 2020 |
|
3.Cardiac:sec.3-22of23-Carotid Endarterectomy and stenting
|
Mar 26, 2020 |
|
3.Cardiac:sec.3-21of23-Anterior Spinal Artery Syndrome
|
Mar 26, 2020 |
|
3.Cardiac:sec.3-20of23-Aortic Cross Clamp
|
Mar 26, 2020 |
|
3.Cardiac:sec.319of23-AAA
|
Mar 26, 2020 |
|
3.Cardiac:sec.1-18of23-Aortic Aneurysm:Classification
|
Mar 26, 2020 |
|
3.Cardiac.sec.3-17of23-Mechanical Cardiac Support
|
Mar 26, 2020 |
|
3.Cardiac:Sec.3-16of23-CPB:key facts
|
Mar 26, 2020 |
|
3.Cardiac:sec.3-15of23-Cardiopulmonary Bypass
|
Mar 26, 2020 |
|
3.Cardiac:sec.3-14of23-PCI (Stents)
|
Mar 26, 2020 |
|
3.Cardiac:sec.3-13of23-Obstructive Hypertrophic Cardiomyopat
|
Mar 26, 2020 |
|
3.Cardiac:sec.3-12of23-Infective Endocarditis
|
Mar 26, 2020 |
|
3.Cardiac:sec.3-11of23-Cardiac Tamponade:Anesthetic mgmt
|
Mar 26, 2020 |
|
3.Cardiac:sec.3-10of23-Cardiac Tamponade
|
Mar 25, 2020 |
|
3.Cardiac:sec.3-9of23-Pericarditis
|
Mar 25, 2020 |
|
3.Cardiac:sec.3-8of123-CCB
|
Mar 25, 2020 |
|
3.Cardiac:sec.3-7of23-Antihypertensive Agents
|
Mar 25, 2020 |
|
3.Cardiac:sec.3-6of23-HTN:secondary
|
Mar 25, 2020 |
|
3.Cardiac:sec.3-5of23-Hypertension
|
Mar 25, 2020 |
|
3.Cardiac:sec.3-4of23-Heart Failure:Systolic bs Diastolic
|
Mar 25, 2020 |
|
3.Cardiac:sec.3-3of23-Diastolic Compliance
|
Mar 25, 2020 |
|
3.Cardiac:Sec.3-2of23-Myocardial O2 Imbalance
|
Mar 25, 2020 |
|
3.Cardiac:Sec.3-1of23-Assessment of Perioperative CV Risk
|
Mar 25, 2020 |
|
3.Cardiac-sec.2-7of7-Pathologic Murmur
|
Mar 25, 2020 |
|
3.Cardiac:sec.2-6of7-Aortic Regurgitation
|
Mar 25, 2020 |
|
3. Cardiac:sec.2-5of7-Mitral Regurgitation
|
Mar 25, 2020 |
|
3.Cardiac:Sec.2-4of7-Mitral Stenosis
|
Mar 25, 2020 |
|
3.Cardiac:sec.1-3of7-Aortic Stenosis
|
Mar 25, 2020 |
|
3.Cardiac:Sec.2-2of7-Concentric & Eccentric Hypertrophy
|
Mar 25, 2020 |
|
3.Cardiac:Sec.2-1of7-Heart Sounds
|
Mar 25, 2020 |
|
3. Cardiac Sec.1-17of17-Regulation of Vascular Smooth Muscle
|
Mar 25, 2020 |
|
3.Cardiac:sec.1-16of17-Myocardial O2 supply & demand
|
Mar 25, 2020 |
|
3. Cardiac Sec.1-15of17-Coronary Perfusion Left vs Right
|
Mar 25, 2020 |
|
3. Cardiac:sec.1-14of17-Coronary Perfusion
|
Mar 25, 2020 |
|
3.Cardiac-sec.1:13of17-Coronary Circultaion
|
Mar 24, 2020 |
|
3.Cardiac.sec.1-12of17-Pressure volume loop step by step
|
Mar 24, 2020 |
|
3. Cardiac Sec.1-11of17-Pressure Volume Loop
|
Mar 24, 2020 |
|
3.Cardiac Sec.10of17-Wiggers Diagram
|
Mar 24, 2020 |
|
3. Cardiac:sec.1-9of17: Afterload
|
Mar 24, 2020 |
|
3.Cardiac: sec.1-8of17-Contractility and Excitation Coupling
|
Mar 24, 2020 |
|
3.Cardiac-sec.1-7of17-Preload and Frank-starling Mechanism
|
Mar 24, 2020 |
|
3.Cardiac Sec.1-6of17-Hemodynamic Calculations
|
Mar 24, 2020 |
|
3. Cardiac Sec.1-5of17-Ohm’s Law
|
Mar 24, 2020 |
|
3.Cardiac Sec.1-4of17-Oxygen Delivery
|
Mar 24, 2020 |
|
3. Cardiac Sec.1-3of17-Cardiac Action Potential:SA Node
|
Mar 24, 2020 |
|
3.Cardiac Sec. 1-2of17-Cardiac Action Potential
|
Mar 24, 2020 |
|
3.Cardiac Sec. 1 Bonus Resting potential
|
Mar 24, 2020 |
|
3.Cardiac Sec.1-1of17-The Myocyte
|
Mar 24, 2020 |
|
2.ANS: 24of24-Alpha Antagonist
|
Mar 24, 2020 |
|
2.ANS:23of24-Beta Antagonist
|
Mar 24, 2020 |
|
2. ANS: 22of 24-Adrenergic Agonist and vasopressin
|
Mar 24, 2020 |
|
2.ANS:21of24-Heart Transplant,Glomangioma, multiple system
|
Mar 24, 2020 |
|
2.ANS:20of24- Occulocardiac,Cushinf,Celiac, Chemoreceptor
|
Mar 24, 2020 |
|
2. ANS:19of24-Bezold-Jarisch and Bainbridge Reflexes
|
Mar 24, 2020 |
|
2. ANS 18of24- Baroreceptor Reflex: Effects of Drugs
|
Mar 24, 2020 |
|
2. ANS:17of24- Baroreceptor Reflex
|
Mar 24, 2020 |
|
2. ANS-16of24- Transcellular potassium shift
|
Mar 16, 2020 |
|
2.ANS-15of24-Adrenal Medulla
|
Mar 16, 2020 |
|
2.ANS-14of24-Sympathetic Ganglia
|
Mar 16, 2020 |
|
2. ANS-13of24- Bird’s eye view of the SNS and PNS
|
Mar 16, 2020 |
|
2.ANS 12of24-Autonomic Reflex Arc
|
Mar 16, 2020 |
|
2.ANS-11of24-ACH synthesis, release & metabolism
|
Mar 16, 2020 |
|
2. ANS-10of24-Catecholamine Metabolism
|
Mar 15, 2020 |
|
2.ANS-9of24-Norepinephrine Termination of Action
|
Mar 15, 2020 |
|
2. ANS-8of24-Norepinephrine Synthesis & Release
|
Mar 15, 2020 |
|
2.ANS-7of24 PDE3
|
Mar 15, 2020 |
|
2. ANS-6of24-Alpha-2 Receptor
|
Mar 15, 2020 |
|
2. ANS-5of24 ANS Receptors & Phy: Part 2
|
Mar 15, 2020 |
|
2. ANS-4of24- Ans receptor ans physiologic Action
|
Mar 15, 2020 |
|
2. AND 3of24- signal transduction: from Receptor to 2nd mess
|
Mar 15, 2020 |
|
2. ANS-2of24-GPCR
|
Mar 15, 2020 |
|
2. ANS-1of24-cellular communication
|
Mar 15, 2020 |
|
1. Respiratory Bonus 3
|
Mar 15, 2020 |
|
1. Respiratory Bonus 2
|
Mar 15, 2020 |
|
1.Respiratory BONUS
|
Mar 15, 2020 |
|
1. Respiratory Sec.2-24of24 HPV
|
Mar 14, 2020 |
|
1. Respiratory Sec.2 23of24- Pulmonary Reflexes
|
Mar 14, 2020 |
|
1. Respiratory Sec.2-22of24 Peripheral Chemoreceptors
|
Mar 14, 2020 |
|
1. Respiratory Sec.2-21of24 Control of Ventilation:Central C
|
Mar 14, 2020 |
|
1. Respiratory Sec.2 20of24-Control of Ventilation:Neural Co
|
Mar 14, 2020 |
|
1. Respiratory Sec.2-19of24-CO2 ventilatory Response Curve
|
Mar 14, 2020 |
|
1. Respiratory Sec.2-18of24- Hypercapnia
|
Mar 14, 2020 |
|
1. Respiratory Sec.2 17of24-Haldane Effect
|
Mar 14, 2020 |
|
1. Respiratory Sec.2 16of24-CO2 transport
|
Mar 14, 2020 |
|
1. Respiratory Sec.2-15of24- Cellular Energetics
|
Mar 14, 2020 |
|
1. Respiratory Sec.2-14of24-Oxyhemoglobin Dissociation Curve
|
Mar 14, 2020 |
|
1. Respiratory Sec.2 13of24-CaO2
|
Mar 14, 2020 |
|
1. Respiratory Sec.2-12of24- Closing volume and Capacity
|
Mar 14, 2020 |
|
1. Respiratory Sec.2-11of24-FRC
|
Mar 14, 2020 |
|
1. Respiratory Sec.2 10of24-Lung Volumes & Capacities
|
Mar 14, 2020 |
|
1. Respiratory Sec.2-9of24-A-a Grdadient
|
Mar 14, 2020 |
|
1. Respiratory Sec.2 8of24-Alveolar Gas Equation
|
Mar 14, 2020 |
|
1. Respiratory Sec.2- 7of24 West Zones
|
Mar 13, 2020 |
|
1. Respiratory sec.2-6of24- Alveolar Surface Tension
|
Mar 13, 2020 |
|
1. Respiratory Sec.2-5of24-V/Q Mismatch
|
Mar 13, 2020 |
|
1. Respiratory Sec.2-4of24-Alveolar Compliance Curve
|
Mar 13, 2020 |
|
1. Respiratory Sec.2-3of24-Dead Space and Vd/Vt
|
Mar 13, 2020 |
|
1.Respiratory sec.2-2of24- Ventilation
|
Mar 13, 2020 |
|
1. Respiratory Sec.2-1of21-Moving air in & out of lungs
|
Mar 13, 2020 |
|
1.Respiratory Sec1-7of7 Lower Airway
|
Mar 09, 2020 |
|
1. Respiratory Sec.1-6of7-Upper Airway Anatomy
|
Mar 09, 2020 |
|
1.Respiratory Sec.1-5of7-Laryngospasm & Larson’s
|
Mar 09, 2020 |
|
1. Respiratory Sec.1-4of7-Laryngeal Anatomy
|
Mar 09, 2020 |
|
1.Respiratory Sec.1-3of7 Infiltration Block larynx
|
Mar 09, 2020 |
|
1. Respiratory Sec.1-2of7 Innervation of upper airway
|
Mar 09, 2020 |
|
1. Respiratory Sec.1-1of7 Laryngeal Muscle
|
Mar 09, 2020 |
|
1. Respiratory Sec.4-21of21 Airway Exchange Catheter
|
Mar 08, 2020 |
|
1. Respiratory Sec.4-20of21 Extubation
|
Mar 08, 2020 |
|
1.Respiratory Sec.4 19of21 Invasive Airways
|
Mar 08, 2020 |
|
1. Respiratory Sec.4-18of21 Retrograde Intubation
|
Mar 08, 2020 |
|
1. Respiratory Sec.4-17of21 Bronchial Blocker
|
Mar 08, 2020 |
|
1.Respiratory sec.4-16of21 Lighted Stylet
|
Mar 08, 2020 |
|
1. Respiratory Sec.4-15of21 Eschmann introducer
|
Mar 08, 2020 |
|
1. Respiratory Sec.4-14of21 Bullard Laryngoscope
|
Mar 08, 2020 |
|
1. Respiratory Sec.4-13of21 Flexible Fiberoptic Bronchoscope
|
Mar 08, 2020 |
|
1.Respiratory Sec.4-12of21 -Combitube
|
Mar 08, 2020 |
|
1.Respiratory Sec.4-11of21 LMA:Special Consideration
|
Mar 08, 2020 |
|
1. Respiratory Sec.4-10of21 LMA:Variations
|
Mar 08, 2020 |
|
1. Respiratory Sec.4 9of21-LMA:Design
|
Mar 08, 2020 |
|
1.Respiratory Sec.4-8of21 ETT design and sizing
|
Mar 08, 2020 |
|
1. Respiratory sec4- 7of21 OPA and NPA
|
Mar 07, 2020 |
|
1. Respiratory Sec.4-6of21 Positioning for Airway mgmt
|
Mar 07, 2020 |
|
1. Respiratory sec.4 5of21 Syndromes Assoc. with difficult
|
Mar 07, 2020 |
|
1. Respiratory sec.4 4of21 Five Questions to ans. B4 airway
|
Mar 07, 2020 |
|
1.Respiratory sec.4 3of21 Laryngeal Assessment Technique
|
Mar 07, 2020 |
|
1. Respiratory Sec. 4 2of21 Airway Assessment P2
|
Mar 07, 2020 |
|
1.Respiratory Sec.4 1of21 Airway Assessment Techniques: 1
|
Mar 06, 2020 |
|
1. Respiratory Sec.3 21of21-Mediastinoscopy
|
Mar 04, 2020 |
|
1. Respiratory Sec.3 20of21 One Lung Ventilation: Part2
|
Mar 04, 2020 |
|
1.Respiratory Sec.3 19of21 One-Lung Ventilation: Part1
|
Mar 03, 2020 |
|
1. Respiratory Sec.3-18of21- Indications of Mechanical Vent
|
Mar 03, 2020 |
|
1. Respiratory Sec.3- 17of21 Carboxyhemoglobin
|
Mar 03, 2020 |
|
1. Respiratory Sec.3- 16of21 Pulmonary HTN
|
Mar 03, 2020 |
|
1. Respiratory Sec.3-15of21 Venous Air Embolism
|
Mar 03, 2020 |
|
1. Respiratory Sec.3- 14of21 Pneumothorax and Flail Chest
|
Mar 03, 2020 |
|
1.Respiratory Sec.3-13of31 Aspiration Pneumonitis & VAP
|
Mar 03, 2020 |
|
1.Respi 12of 31 Cystic Fibrosis
|
Mar 03, 2020 |
|
1. Respiratory Sec3-12of21 Restrictive Lung Disease
|
Mar 03, 2020 |
|
1.Respi sec.2- 11of21 Dynamic Hyperinflation (Auto-PEEP)
|
Mar 02, 2020 |
|
1.Respiratory-Sec.3- 10of21 COPD:Anesthetic Mgmt
|
Mar 02, 2020 |
|
1.Respi-sec3-9of21 COPD
|
Mar 02, 2020 |
|
1. Respi-sec3- 8of21 Intraoperative Bronchospasm
|
Mar 02, 2020 |
|
1.Respiratory Sec.3- 7of21 Asthma
|
Mar 01, 2020 |
|
1.Respiratory-sec3- 6of21 Obstructive vs Restrictive
|
Mar 01, 2020 |
|
1.Respiratory Sec.3 5of21- Post-op pulmonary complications
|
Mar 01, 2020 |
|
1.Respiratory Sec.3 4of21- Flow-Volume Loops
|
Mar 01, 2020 |
|
1.Respiratory-Sec.3-3of21-PFT
|
Mar 01, 2020 |
|
1. Respiratory Sec.3 2of21Pulmonary Pharmacology
|
Mar 01, 2020 |
|
1. Respiratory-Sec3- 1of21 Control of Airway Diameter
|
Mar 01, 2020 |
|
Test
|
Mar 01, 2020 |